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Abstract
Decorin, small leucine-rich proteoglycan, has been shown to modulate angiogenesis in nonocular tissues. This study tested
a hypothesis that tissue-selective targeted decorin gene therapy delivered to the rabbit stroma with adeno-associated virus
serotype 5 (AAV5) impedes corneal neovascularization (CNV) in vivo without significant side effects. An established rabbit
CNV model was used. Targeted decorin gene therapy in the rabbit stroma was delivered with a single topical AAV5 titer
(100 ml; 561012 vg/ml) application onto the stroma for two minutes after removing corneal epithelium. The levels of CNV
were examined with stereomicroscopy, H&E staining, lectin, collagen type IV, CD31 immunocytochemistry and CD31
immunoblotting. Real-time PCR quantified mRNA expression of pro- and anti-angiogenic genes. Corneal health in live
animals was monitored with clinical, slit-lamp and optical coherence tomography biomicroscopic examinations. Selective
decorin delivery into stroma showed significant 52% (p,0.05), 66% (p,0.001), and 63% (p,0.01) reduction at early (day 5),
mid (day 10), and late (day 14) stages of CNV in decorin-delivered rabbit corneas compared to control (no decorin delivered)
corneas in morphometric analysis. The H&E staining, lectin, collagen type IV, CD31 immunostaining (57–65, p,0.5), and
CD31 immunoblotting (62–67%, p,0.05) supported morphometric findings. Quantitative PCR studies demonstrated
decorin gene therapy down-regulated expression of VEGF, MCP1 and angiopoietin (pro-angiogenic) and up-regulated PEDF
(anti-angiogenic) genes. The clinical, biomicroscopy and transmission electron microscopy studies revealed that AAV5–
mediated decorin gene therapy is safe for the cornea. Tissue-targeted AAV5-mediated decorin gene therapy decreases CNV
with no major side effects, and could potentially be used for treating patients.
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Introduction
Corneal neovascularization (CNV) is a sight-threatening
condition resulting from various corneal insults such as infection,
trauma, chemical burns, inflammation, limbal insufficiency,
allergic eye diseases, etc [1,2]. Over 4% of the US population is
estimated to have CNV, with 1.4 million Americans developing
this disorder annually and 12% of these patients suffers with
decreased visual acuity [3]. The clinical management of CNV
represents a formidable challenge as current pharmacotherapeutic
and surgical options are associated with serious complications, are
not always effective, and may fail altogether necessitating corneal
transplant. Currently, corticosteroids form the cornerstone for
treating CNV but are at times ineffective and may lead to adverse
side effects including cataracts, glaucoma, and infection [4]. More
recently, an anti-vascular endothelium derived growth factor
(VEGF) antibody has been tested in patients to treat CNV [5]. In
addition, a few other anti-angiogenic proteins have been evaluated
to treat CNV [6,7]. Nonetheless, all current therapies to treat
CNV are inefficient, provide only short-term relief, cause serious
side effects and are often ineffective. Furthermore, the therapeutic
efficacy of topical ophthalmic drugs is greatly compromised due to
the drug’s poor permeability to the cornea, inability to permeate
the corneal epithelial barrier, and rapid turnover due to tear fluid
and nasolacrimal drainage [8].
Gene therapy is an attractive approach to treat CNV. The
cornea is an ideal organ for gene therapy because of its immune-
privileged status, ease of administering gene therapy reagents and
visual monitoring. The potential of gene therapy to treat CNV has
been demonstrated using genes such as angiostatin, PEDF, Flt-1,
and soluble vascular endothelium growth factor receptor [9–12].
However, ineffective delivery of therapeutic genes into targeted
cells often leads to numerous side effects and sharply limits clinical
usefulness of gene therapy in patients. We identified multiple
adeno-associated virus (AAV) serotypes efficient and safe for
delivering foreign genes into rodent, rabbit, equine, and human
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cornea in vitro and in vivo [13–18]. Other investigators also found
AAV effective for delivering genes in the cornea [10,19,20].
Recently, we demonstrated tissue-targeted gene delivery in the
stroma of the normal and damaged (hazy or neovascularized)
rabbit cornea in vivo using a combination of AAV5 and custom
vector-delivery techniques [Mohan RR, et al. Invest Ophthalmol
Vis Sci. 2005, 46 E-Abstract 2163]. Gene delivery into stroma
with this method did not cause any visual short-term side effects in
the rabbit eye. It has been our hypothesis that AAV-mediated
targeted delivery of anti-angiogenic genes in the corneal stroma
effectively decrease CNV without causing significant side effects.
The cornea contains numerous pro-angiogenic and anti-
angiogenic factors, and a shift in the balance between these two
factors triggers blood vessel growth in the avascular cornea [1,2].
The precise molecular mechanism causing CNV is still unknown.
Vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (FGF2) are known to induce CNV in vivo [1,2].
Sprouting of new blood vessels in the cornea towards an implanted
VEGF or FGF2 pellet strongly supports this notion. Decorin, a
small leucine-rich proteoglycan, has been shown to be expressed in
the cornea and is known to play a vital role in fibrillogenesis and
extracellular matrix (ECM) and angiogenesis regulation [21,22].
Recent research has demonstrated that decorin suppresses
endothelial migration as well as the formation of vascular tubes,
implicating it’s role in angiogenesis [23,24]. Sulochana et al.
showed anti-angiogenic properties of decorin are mediated by the
inhibition of endothelial cell migration [25]. Further support for
decorin’s anti-angiogenic properties comes from an in vivo study
performed in nude mice that demonstrated decreased angiogenesis
in tumor xenografts that over-express decorin [26]. These literary
reports prompted us to hypothesize that targeted delivery of
decorin into rabbit stroma with recently defined tissue-selective
gene transfer technique would effectively inhibit CNV with
minimal side effects. This study tested the hypothesis by
introducing decorin gene into the rabbit cornea stroma with
AAV5 via a custom vector delivery technique after CNV was
induced with VEGF using a micro-pocket assay.
Results
Validation of Decorin Gene Delivery
The delivery of decorin gene with a single topical application of
AAV5-dcn vector in the rabbit cornea was validated with western
blotting. Figure 1A shows the levels of detected decorin in naive,
control (no decorin) and decorin-delivered rabbit corneas. The
protein lysates prepared from the AAV5-dcn treated corneas
showed significant 8.760.4 (p,0.05) fold higher levels of decorin
confirming substantial delivery of therapeutic gene, decorin, in the
rabbit corneas with selected AAV serotype. Contrary to this, very
weak bands of decorin detected in the naive and naked-AAV5
vector treated rabbit corneas confirmed the low endogenous
expression of decorin protein in the rabbit cornea.
Injury to corneal epithelium has been shown to cause keratocyte
apoptosis as well as infiltration of inflammatory, bone marrow
derived and other cells in the stroma [27,28]. TUNEL data shown
in Figure 1B demonstrates that defined corneal deepithelialization
technique (gentle removal of corneal epithelium by running #64
surgical blade at 45u angle) for gene therapy induces minimal
keratocyte death in rabbit corneas collected 4 hours compared to
the corneas in which epithelium was removed using #64 blade
with no particular angle, pattern or care. As evident from
Figure 1B, rabbit corneal sections of defined technique showed
Figure 1. Representative immunoblot (A) and TUNEL assay (B) of rabbit corneas receiving AAV5-decorin or AAV5-gfp. Representative
western blotting showing AAV5-controlled decorin delivery in rabbit corneas collected 14 days after VEGF-implantation (A) and TUNEL assay
detecting keratocyte apoptosis in rabbit corneas collected 4 hours after epithelial removal by two different ways (B). A strong band in AAV5-dcn
treated rabbit corneas of day-14 time point reveals significant decorin delivery (8.7-fold, p,0.05) in the stroma, and a weak decorin band in naive or
AAV5-gfp treated corneas indicates low endogenous decorin expression (A). GAPDH was used to confirm equal protein loading in each well and
normalization of the data. TUNEL-stained rabbit corneal sections of 4-hour time point shown in Panel B demonstrate minimal keratocyte apoptosis
(arrow) in cornea deepithelialized via gentle scrapping with #64 surgical blade by running blade at 45u angle (left panel) compared to high
keratocyte death in cornea in which epithelium was removed in random manner with #64 surgical blade (right panel). Scale bar denotes 100 mm.
dcn=decorin.
doi:10.1371/journal.pone.0026432.g001
AAV-Decorin Gene Therapy for Corneal Angiogenesis
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,5% TUNEL+ cells (left panel) in the stroma compared to the
sections of the rabbit corneas in which epithelium was removed by
fast and random scraping (right panel). As expected, naive corneas
showed TUNEL+ cells only in epithelium (data not shown).
Morphometric quantification of CNV in Decorin-delivered
and Non-delivered Rabbit Eye
Figure 2 shows stereomicroscopic images depicting the area,
length and density of VEGF-induced blood vessels in decorin-
delivered and no decorin-delivered (control) rabbit corneas
observed at 3 different time points. Implanted VEGF produced
a strong angiogenic response as evidenced by the presence of
blood vessels in avascular regions of the cornea. The peak
angiogenic response in control corneas that received AAV5-naked
or AAV5-gfp vector was observed on day 10. Decorin-delivered
rabbit corneas showed significant decrease in the area, length,
thickness and density of the blood vessels at the early- (day 5;
Fig 2B), mid- (day 10; Fig 2D) and late- (day 14; Fig 2F) stages of
CNV compared to corresponding control (no decorin-delivered)
corneas (Fig. 2A, 2C and 2E). To quantify the efficacy of AAV5-
mediated decorin gene therapy, area, length and density of blood
vessels in the cornea was determined with NIH software Image J.
Figure 3 shows mean corneal vasculature area detected in decorin-
delivered and control (no decorin-delivered) rabbit corneas at
three time points namely 5, 10 and 14 day which represent early,
mid and late stages of CNV, respectively. The control corneas
(AAV5-naked or AAV5-GFP treated) showed a mean vasculature
area of 10 mm2 at day 5, 12.7 mm2 at day 10, and 10.3 mm2 at
day 14. Contrary to this, decorin-delivered rabbit corneas showed
mean CNV area of 4.8 mm2 on day 5, 4.3 mm2 on day 10, and
3.8 mm2 on day 14. The relative comparison of CNV data
between the control and decorin-delivered corneas revealed a
statistically significant reduction in corneal neovascularization by
5265.5% on day 5 (y=p,0.05), 6666.5% on day 10
(* = p,0.001), and 6366.3% on day 14 (f=p,0.01) (Fig. 3).
Histological comparison of CNV in Decorin-delivered and
Non-delivered Corneal Tissues
Figure 4 shows localization and density of blood vessels in
control and decorin-delivered tissue sections of rabbit corneas
collected 14 days after VEGF-pellet implantation. Serial sections
were prepared. As expected, corneal sections obtained from the
peripheral region of the cornea closer to the limbus showed many
large-diameter blood vessels (Fig 4A and 4B) whereas corneal
sections prepared from the region closer to VEGF pellet showed
numerous small-diameter blood vessels (Fig 4C and 4D). The
H&E staining performed in the corneal sections of the AAV5-
naked and AAV5-dcn vector groups obtained from the same
peripheral regions showed markedly less number and reduced-
diameter blood vessels in the decorin-delivered rabbit corneas
(Fig 4B) compared to the control cornea (Fig. 4A). Similar anti-
angiogenic effects of decorin gene therapy were noted in the H&E
stained corneal sections prepared from the region closer to the
VEGF pellet as decorin-delivered rabbit corneas (Fig 4D)
demonstrated significantly (p,0.01) fewer and thin-diameter
blood vessels compared to control corneas (Fig. 4C).
The inhibitory effects of decorin gene therapy on CNV were
further confirmed by performing immunostaining of angiogenesis
markers in the tissue sections of rabbit corneas collected 14 days
after VEGF-pellet implantation. Tomato lectin specifically stains
blood vessels by binding to the components of basement
membrane whereas collagen type IV is a component of basal
lamina of blood vessels and CD31 is another endothelial marker.
Figure 5 shows the results of lectin (Figs. 5A–F) and collagen type
IV (Figs. 5G–L) immunostaining performed in no-decorin (AAV5-
gfp-treated) and decorin-delivered (AAV5-dcn-treated) rabbit
corneas collected on day-14. Significantly less lectin+ (Fig 5E
and 5F; 6,8596393 pixels/200x magnification, p,0.01) and
collagen type IV+ (Fig 5K and 5L; 1,9836187 pixels/200x
magnification, p,0.01) cells were detected in decorin-delivered
rabbit corneas compared to no decorin-delivered control corneas
stained for lectin (Fig 5B and 5C; 26,6086713 pixels/200x
magnification) or collagen type IV (Fig 5H and 5I; 6,6466259
pixels/200x magnification). The digital quantification of lectin+
and collagen type IV+ cells detected 59–65% (p,0.01) decrease in
VEGF-induced corneal vasculature by AAV5-dcn gene transfer in
rabbits in vivo. Immunostaining using another endothelial marker,
CD31, showed similar results (data not shown). These immuno-
histochemistry investigations suggest that AAV5-mediated decorin
gene therapy is highly effective in reducing neovascularization in
the rabbit experimental model of CNV.
Immunoblotting Quantification of CNV in Decorin-
delivered and Non-delivered Corneas
The efficacy of AAV5-dcn gene therapy was also analyzed by
performing western blotting of CD31, a pan-endothelial marker
found in blood vessels, platelets, granulocytes, and monocytes that
are involved in the formation of new blood vessels. Figure 6 shows
results of CD31 western blotting performed with protein lysates
prepared from control and decorin-delivered rabbit corneas
collected 10 or 14 days after VEGF implantation. As evident
from Fig 6, AAV-mediated decorin delivery in rabbit corneas
reduced CD31 expression 6263% (p,0.05) on day-10 and
6766% (p,0.05) on day14 suggesting that maximal inhibition
was attained by day-10 and then continued until the longest tested
time point of day-14. The detection of similar intensity b-actin
bands confirmed equal loading of protein samples.
Decorin Gene Therapy Modulates Expression of Pro- and
Anti-angiogenic Factors
To investigate the possible molecular mechanism of decorin
gene therapy for inhibiting CNV, the expression of pro-angiogenic
factors such as VEGF, MCP1, angiopoietin and anti-angiogenic
factors such as PEDF was analyzed in naive, control (no-decorin)
and decorin-delivered rabbit corneas collected 14 days after
VEGF-implantation. Figure 7 shows the relative change in the
expression of VEGF, MCP1, angiopoietin, and PEDF genes in the
cDNA sample of the naive, control (no-decorin) and decorin-
delivered rabbit corneas. All cDNA samples with VEGF-induced
CNV showed statistically significant increase in VEGF and MCP1
and a less pronounced increase in angiopoietin as compared to
cDNA samples obtained from naive corneas. The decorin-
delivered corneas showed a significant decrease in VEGF
expression (5 fold, p,0.05) and MCP1 (3 fold, p,0.05). Contrary
to this, decorin-delivered cornea showed lower angiopoietin and
mildly increased PEDF expression, however, data was not
statistically significant (Fig. 7).
Slit-lamp and Optical Coherence Tomography
Biomicroscopy and Transmission Electron Microscopy
Investigations
Visual and slit-lamp clinical examination performed in the eyes
of live rabbits did not detect any abnormality in non decorin-
delivered or decorin-delivered corneas with AAV5 at all tested
time points. No haziness, swelling, redness or infection was
detected in visual clinical eye examination except in the region
AAV-Decorin Gene Therapy for Corneal Angiogenesis
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where VEGF pellet was implanted. As expected, several blood
vessels sprouting from the limbus towards the VEGF pellet were
observed in clinical examination. Optical coherence tomography
did not detect alteration in corneal structure, thickness or shape of
the stroma in decorin-delivered and no decorin-delivered rabbit
corneas (Fig 8A and 8B). Furthermore, TEM analysis of naive and
decorin-delivered rabbit corneas did not detect any significant
differences between the collagen fibril diameter and arrangement
in the stroma (Fig 8C and 8D). Slit-lamp, optical coherence
tomography and TEM data allowed us to infer that targeted
decorin gene transfer into stroma does not affect optical and
structural properties of the cornea, and consequently visual
function.
Discussion
Corneal neovascularization is a serious pathological condition
often requiring aggressive and prolonged treatment for its effective
Figure 2. Representative stereomicroscopy images showing VEGF-induced CNV in no decorin-delivered control (A, C and E) and
decorin-delivered (B, D and F) rabbit corneas. Rabbit eyes were imaged early (5 day, Panels A, B), mid (10 day, Panels C, D), and late (14 day,
Panels E, F) stages after VEGF pellet implantation. The 100 ml AAV5 viral titer (561012 vg/ml) expressing no gene/gfp or decorin was topically applied
onto the cornea after removing corneal epithelium for single application for 2 minutes. A statistically significant inhibition of neovascularization was
observed at three tested early, mid and late stages of the CNV. Scale bar denotes 2 mm. dcn= decorin.
doi:10.1371/journal.pone.0026432.g002
AAV-Decorin Gene Therapy for Corneal Angiogenesis
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management. Gene therapy offers a unique opportunity for
treating CNV by providing long-term expression of therapeutic
genes in the cornea. In this study, we demonstrated significant
inhibition of VEGF-induced CNV with decorin gene therapy
delivered in rabbit eyes in vivo via AAV vector. The vector was
administered to the cornea with a custom vector-delivery
technique optimized recently in our laboratory [29]. Previously,
we demonstrated long-term transgene expression in the cornea
with AAV [14]. Recently, we examined the efficacy of multiple
AAV serotypes (2, 5, 7, 8 and 9) for corneal gene therapy, and
found AAV serotypes 5, 8 and 9 efficient for transducing rabbit
and rodent corneas [13–18]. In this study, AAV serotype 5 was
utilized because this vector was used to optimize targeted delivery
of therapeutic genes in the stroma of normal and damaged rabbit
corneas [14]. Earlier studies performed with AAV2-mediated anti-
angiogenic gene therapy to treat CNV showed 30–50% reduction
in CNV [10,20]. A more robust inhibition of CNV (up to 67%)
observed in this study with AAV5 is most likely due to the superior
transduction efficiency of the AAV5 serotype. The detection of no
apparent side effects in rabbit eye supports our hypothesis that
targeted introduction of therapeutic genes in the cornea is an
effective approach to treat corneal diseases with minimal side
effects.
Decorin is a chondroitin/dermatan sulfate-containing small
leucine rich proteoglycan that modulates several essential
biological processes in the corneal tissue including collagen
fibrillogenesis [21,22]. Recent studies have implicated the role of
decorin in modulation of angiogenesis with decorin over-
expression via retroviral transduction showing considerable
inhibition of vascular endothelial cell migration [24]. Purified
decorin obtained from cartilage and skin tissue has been shown to
curtail vascular endothelial cell migration as well as tube formation
in an in vitro model [23]. In addition to in vitro studies, decorin has
also been reported to inhibit angiogenesis in tumor xenograft in
vivo in nude mice [26]. These studies support the results of this
present study, which demonstrate significant inhibition of VEGF-
Figure 3. Morphometric quantification of CNV from different
time points in rabbit eyes receiving AAV5+/2decorin. Data was
collected after day 5 (early), 10 (mid), and 14 (late) of VEGF implantation
from the control (no decorin-delivered) and decorin-delivered rabbit
corneas. AAV-mediated decorin gene therapy demonstrated statistically
significant decrease at the three tested stages of the CNV in rabbit
model in vivo. y=p,0.05, * = p,0.001, f=p,0.01 compared to
control. dcn =decorin.
doi:10.1371/journal.pone.0026432.g003
Figure 4. Representative H&E staining images showing anti-angiogenic efficiency of decorin gene therapy in rabbit corneas. The
decorin-delivered rabbit corneas (B and D) showed a statistically significant (p,0.01) reduction in vasculature area, density, and blood vessels
number, length and diameter compared to control (no decorin-delivered) rabbit corneas (A and C) collected 14 days after VEGF implantation. The
images shown in panels A and B are from the corneal sections obtained from the peripheral region of the cornea closer to the limbus whereas the
images shown in panels C and D are from the corneal sections proximal to the VEGF pellet. Scale bar denotes 100 mm. dcn= decorin.
doi:10.1371/journal.pone.0026432.g004
AAV-Decorin Gene Therapy for Corneal Angiogenesis
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Figure 5. Representative images showing CNV in rabbit corneas treated AAV5+/2decorin. Lectin (A–F) and collagen type IV (G–L)
immunostaining was carried out in corneal tissue sections obtained from AAV5-gfp and AAV5-dcn treated rabbit corneas collected 14 days after VEGF
implantation. As expected very high lectin (A–C) and collagen type IV (G–I) immunostaining was detected in the corneal sections of AAV5-gfp-treated
(no decorin-delivered) corneas due CNV induced by the VEGF implantation. The AAV5-mediated decorin gene therapy significantly reduced (p,0.01)
the CNV as evident from the markedly less lectin+ (D–F) and collagen type IV+ (J–L) cells in decorin-delivered rabbit corneal sections. DAPI stained
nuclei are shown in blue whereas lectin and collagen type IV+ cells in red. Scale bar denotes 100 mm. dcn= decorin.
doi:10.1371/journal.pone.0026432.g005
Figure 6. CD31 Western blot for naive, AAV5+/2decorin-delivered rabbit corneal tissues collected 10 and 14 days after VEGF-
implantation. Panel on left side shows immunoblot and on right side shows quantification of western blotting data collected from corneal tissues
of day-10 and day-14. A significant decrease in expression of CD31 on day-10 (62%, p,0.05) and day-14 (66%, p,0.05) was detected in decorin-
delivered corneas compared to control corneas suggesting that AAV5-mediated decorin gene therapy is efficient in decreasing CNV. b-actin was used
to confirm equal loading of protein in each well and normalization of the data. dcn= decorin.
doi:10.1371/journal.pone.0026432.g006
AAV-Decorin Gene Therapy for Corneal Angiogenesis
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Figure 7. Quantification of mRNA expression of pro- and anti-angiogenic genes by real-time PCR. Real-time PCR was carried out in
naive, control (no decorin-delivered) and decorin-delivered rabbit corneal tissues collected 14 days after VEGF implantation. Decorin gene therapy
delivered with AAV5 showed marked decrease in the mRNA expression of VEGF and MCP-1 and less pronounced alteration in angiopoietin and PEDF
genes. Our data suggests anti-angiogenic effects of decorin gene therapy are mediated by the down-regulation of pro-angiogeneic (VEGF, MCP1 and
angiopoietin) and up-regulation of anti-angiogenic (PEDF) genes. * = p,0.001 compared to naive; f=p,0.05 compared to naive; y=p,0.05
compared to no decorin (dcn)-delivered.
doi:10.1371/journal.pone.0026432.g007
Figure 8. Representative optical coherence tomography (A and B) and transmission electron microscopy (C and D) images of
rabbits receiving AAV5-gfp or AAV5-dcn. Optical coherence tomography was performed in live rabbits on day 10 after the AAV5-gfp or AAV5-
dcn application and transmission electron microscopy was performed in corneas collected 14 days after AAV5-gfp or AAV5-dcn application. The
optical scans of no decorin-delivered (A) and decorin-delivered (B) cornea suggest that tissue-selective targeted delivery of decorin gene with AAV5
in the rabbit stroma does not induce changes in corneal structure, thickness or shape. The TEM did not detect significant differences in collagen fibril
diameter and arrangement in the naive (C) and decorin-delivered rabbit corneas (D) indicating that localized therapeutic levels of decorin delivery in
the cornea does not appear compromise corneal health. dcn= decorin.
doi:10.1371/journal.pone.0026432.g008
AAV-Decorin Gene Therapy for Corneal Angiogenesis
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induced corneal angiogenesis by decorin gene transfer in vivo in a
rabbit experimental model of CNV. To the best of our knowledge,
this is the first study to demonstrate the potential use of decorin
gene therapy for treating corneal angiogenesis in vivo. The VEGF-
induced corneal micropocket assay used in this study is most
reliable and appropriate model for identifying potent anti-
angiogenic agents and developing newer strategies for potential
therapies [1,2,29–31]. This in vivo model is frequently used in
angiogenesis research because of low inflammatory response and
minimal confounding effects of wound healing, and allows better
understanding of molecular mechanism associated with corneal
angiogenesis. VEGF is a known initiator and promoter of
angiogenesis, and its implantation in the stroma has been shown
to induce robust neovascularization in the cornea by stimulating
new blood vessels growth towards the transparent cornea from
limbal region [1,2,30]. However, it can be argued that in VEGF-
induced model angiogenesis is not associated with trauma, injury
or infection, which are known to trigger CNV in human patients.
In order to fully define clinical translational potential of AAV-
decorin gene therapy for treating corneal neovascularization in
patients additional in vivo studies employing inflammation-based
animal model such as alkali burn, chemical cauterization etc are
warranted.
Decorin has been shown to interact with a wide variety of
bioactive molecules including VEGF [21,25,26,32]. Studies
investigating the molecular mechanism of decorin have shown
that decorin inhibits angiogenesis by suppressing VEGF or FGF
expression [25,26]. Angiogenesis is a complex process involving
interplay between a wide variety of pro- and anti-angiogenic
factors [1,2]. In the present study, the relative expression of well-
known pro- and anti-angiogenic genes such as VEGF, MCP1,
angiopoietin and PEDF was analyzed to understand the molecular
mechanism of decorin-mediated inhibition of CNV. A marked
decrease in the expression of VEGF suggests that anti-angiogenic
effects of decorin in the rabbit eye are likely due to the attenuation
of VEGF. In the cornea, as well as other tissues, it is reported that
VEGF stimulates VEGF mostly through paracrine mechanism by
recruiting macrophages or increasing expression of other proan-
giogenic factors that, in turn, enhance VEGF expression [33,34].
Our study detecting significantly high level of VEGF in VEGF-
implanted corneas is in agreement with these literature findings.
Furthermore, observed decrease in VEGF mRNA in our study
may possibly due to direct inhibition of VEGF gene expression by
decorin as reported earlier for non-ocular tissues [26]. It is also
possible that decorin may be decreasing VEGF indirectly by
modulating other cytokines as decorin is a known ligand for
several growth factors and cytokines [22]. This remains to be
tested. A small change observed in the MCP1, angiopoietin and
PEDF gene expression indicate that they play a less prominent role
in decorin-mediated CNV gene therapy in the cornea. More
studies to unveil the role of decorin on pro- or anti-angiogenic
factors are required to understand the molecular mechanism
associated with decorin gene therapy in the cornea. Mimura et al
[35] reported that metalloproteinases regulate FGF-induced CNV
by causing breakdown of corneal decorin. Therefore, one of the
mechanisms by which decorin gene therapy may have prevented
angiogenesis is by saturating these metalloproteinases and thus
protect endogenous corneal decorin from degradation. Our future
studies will address such issues.
Optical coherence tomography imaging is frequently used in
ophthalmology clinic to diagnose and image anomalies in eye
tissues [36]. The impact of AAV-decorin gene therapy on the
cornea and neighboring ocular tissues were recorded and
suggested that AAV-mediated decorin gene therapy does not
compromise corneal or other ocular tissues. A decorin knockout
mice study exhibited that targeted disruption of decorin may
compromise collagen fibril morphology and skin fragility [37,38].
Thus, there exists a theoretical possibility that decorin gene
therapy could affect collage organization in the cornea. To address
this legitimate concern, we performed transmission electron
microscopy studies, and detected no significant differences in
collagen fibril diameter and/or arrangement in decorin-delivered
rabbit corneas collected after 2 weeks (Fig 8) suggesting that
therapeutic levels of delivered decorin does not alter corneal
collagens at least for short-term. However, long-term (a year or
longer) AAV-decorin toxicity studies are warranted.
In summary, this study demonstrates for the first time significant
inhibition of corneal neovascularization in the rabbit cornea with
no short-term side effects by AAV5-mediated tissue targeted
decorin gene therapy. Furthermore, the results of this study
support our hypothesis that tissue-selective delivery of therapeutic
genes in the stroma with defined gene therapy approaches may
effectively decrease corneal disease severity without insignificant
side effects.
Materials and Methods
Animals and Micro-pocket Corneal Neovascularization
Assay
Twenty-four female New Zealand White rabbits (Myrtle
Laboratories Inc., Thompson’s Station, TN) weighing 2.5–3.0 kg
were used in this study. The Institutional Animal Care and Use
Committee of the University of Missouri-Columbia and Harry S.
Truman Memorial Veterans’ Hospital, Columbia approved the
study. Animals were treated in adherence to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
Corneal angiogenesis in rabbit eyes was induced by corneal micro-
pocket assay [29]. Rabbits were anesthetized by intramuscular
injection of ketamine hydrochloride (50 mg/kg) and xylazine
hydrochloride (10 mg/kg), and 3–4 drops of 0.5% proparacaine
hydrochloride solution (Alcon, Ft. Worth, TX) was topically
applied to the eye prior to micro-pocket surgery. Only one eye of
each animal was used for the surgical procedure. The contralateral
eye served as naive control. A wire speculum was positioned in the
eye, and a sucralfate-hydron pellet containing 650 ng of VEGF
(PeproTech, Rocky Hill, NJ) was implanted into the cornea after
making a micro-pocket in the stroma using standard surgical tools.
Triple antibiotic ointment (Alcon) was applied to the surface of the
cornea after pellet implantation to prevent infection. The ingrowth
of blood vessels in the cornea towards VEGF implant started from
day 2, peaked around day 10, and continued to grow progressively
up to 15 days before regressing.
AAV5 Vector Expressing Decorin
Decorin gene was amplified with PCR from the cDNA of
primary rabbit corneal fibroblasts using forward (59GAT CGC
GGC CGC AAT CAT GAC GGC AAC TCT CAT C39) and
reverse (59GTC AGC GGC CGC GAG TTA CTT GTA GTT
TCC GAG C39) primers. The resulting template was cloned into
the Not1 site of AAV2 plasmid pTRUF11 containing a hybrid
promoter (cytomegalovirus enhancer and chicken b-actin) and
simian virus 40 polyadenylation site. The resultant decorin cloned
plasmid was packaged into AAV5. In brief, decorin AAV5 vector
was produced by the 2-plasmid, co-transfection method [39].
One Cell Stack (Corning Inc., Corning, NY) with approximately
16109 HEK 293 cells was cultured in Dulbecco’s Modified
Eagle’s Medium (Hyclone Laboratories Inc. Logan UT),
supplemented with 5% fetal bovine serum and antibiotics. A
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CaPO4 transfection precipitation was set up by mixing a 1:1
molar ratio of decorin AAV2 plasmid DNA and AAV5 rep–cap
helper plasmid DNA. This precipitate was applied to the cell
monolayer and the transfection was allowed to incubate at 37uC,
7% CO2 for 60 h. The cells were then harvested and lysed by
freeze/thaw cycles and subjected to discontinuous iodixanol
gradients centrifugation at 350,000 g for 1 h. This iodixanol
fraction was further purified and concentrated by column
chromatography on a 5-ml HiTrap Q Sepharose column using
a Pharmacia AKTA FPLC system (Amersham Biosciences,
Piscataway, NJ). The vector was eluted from the column using
215 mM NaCl, pH 8.0, and the rAAV peak collected. AAV5
decorin (AAV5-dcn) vector-containing fraction was then concen-
trated and buffer exchanged in Alcon BSS with 0.014% Tween
20, using a Biomax 100 K concentrator (Millipore, Billerica,
MA). Vector was titered for DNAse-resistant vector genomes by
real-time PCR relative to a standard.
AAV5 Transduction to Rabbit Cornea
The rabbits were divided into two groups. 100 ml titer
(561012 vg/ml) of AAV5 naked vector or green fluorescent
protein gene expressing (AAV5-gfp) vector (n = 12) or AAV5
vector expressing decorin gene (n = 12) was topically applied to the
stroma for two minutes one day after VEGF pellet implantation
using a custom-delivery technique [32]. Briefly, the corneal
epithelium of the rabbit corneas was removed by gentle moving
of #64 Beaver blade (Becton–Dickinson, Franklin Lakes, NJ) at
45u angle over the corneal surface under an operating microscope
while the animal was under general and local anesthesia. After
removing corneal epithelium, eyes were washed with balanced salt
solution (Alcon) and wiped with a merocel sponge. A Conair hair
dryer of 234 watts (Model 1875; Conair, Stamford, CT) was used
for dehydrating the corneas for three cycles of 10 s with 5 s interval
after each round. The temperature and air-flow of warm air were
41uC and 6.8 m/s, respectively, according to digital Velocicheck
anemometer (Model 8330; TSI Inc., Shoreview, MN). The
corneal dehydrating devise was operated from a distance of 8
inches and approximately 45u angle to the eye. Immediately after
drying, vector was topically applied using a polystyrene cloning
cylinder having 7 mm diameter. The AAV5-gfp or AAV5 naked
vector served as a control group to the AAV5-dcn treated group.
The contralateral eyes served as a naive control.
Clinical, Slit-lamp and Optical Coherence Tomography
Examinations
The health of the cornea in the eyes of live rabbits was
examined by visual clinical and slit-lamp microscopic (BX 900
Slit Lamp, Haag-Streit-USA, Mason, OH) examinations before
and after the VEGF pellet implantation or AAV application by
two ophthalmologists and a researcher, independently in a
blinded manner while animals were under general anesthesia.
Thereafter, corneal health was monitored every 3rd day with a
hand-held slit-lamp microscope (SL-15, Kowa Optimed Inc.,
Torrance, CA). Photographs of the cornea were taken with a
digital camera attached to the BX 900 slit-lamp microscope. To
investigate the corneal structure, corneal thickness and shape of
the stroma, optical coherence tomography was performed using
Cirrus 3000 high-definition instrument (Carl Zeiss Meditec,
Dublin, CA) in control and decorin-delivered rabbits under
general anesthesia. The scans with the best signal strength were
selected, and imaging data was analyzed with Cirrus optical
coherence tomography system software (version 3.0; Carl Zeiss
Meditec, Dublin, CA).
Quantification of Corneal Neovascularization with
Stereomicroscopy
The level of neovascularization in the corneas of all 20 rabbits
was monitored and quantified with a micrometer-calibrated
stereomicroscope (Leica, Wetzlar, Germany) equipped with a
digital camera (SpotCam RT KE, Diagnostic Instruments Inc.,
Sterling Heights, MI). Rabbit eyes were imaged at 5, 10, and 14
days after pellet implantation for determining the efficacy of
decorin therapy to inhibit CNV. Adobe Photoshop CS2 (Adobe
systems, San Jose, CA) and National Institutes of Health Image J
1.38X (NIH, Bethesda, MD) software were utilized to quantify
CNV in the rabbit eye.
Tissue Collection
Rabbits were humanely euthanized with pentobarbitone
(150 mg/kg) overdose under general anesthesia on day 10 (n= 4)
or 14 (n= 20) after VEGF pellet implantation. Corneas were
removed with forceps and sharp Westcott scissors, embedded in
liquid optimal cutting temperature (OCT) compound (Sakura
FineTek, Torrance, CA) within a 24 mm624 mm65 mm mold
(Fisher, Pittsburgh, PA) and snap frozen. Frozen tissue blocks were
maintained at 280uC. Tissue sections were cut 7 mm thick with a
cryostat (HM 525 M, Microm GmbH, Walldorf, Germany).
Sections were placed on 25 mm675 mm61 mm microscope
Superfrost Plus slides (Fisher), and maintained frozen at 280uC
until staining. The excised rabbit corneal tissues were immediately
dropped in liquid nitrogen and used for RNA or protein extraction
or fixed for TEM analysis. The distribution of 20 rabbits for day-
14 was: n= 10 for AAV-gfp, n= 10 for AAV-dcn (6 corneas for
immunohistochemistry, 2 corneas for immunoblotting, and one
half of 2 corneas for RT-PCR and other half for TEM), and day-
10 four rabbit corneas (2 AAV-gfp and 2 AAV-dcn treated) were
used for immunoblotting.
Immunohistochemistry and H&E staining
Corneal tissues were stained for hematoxylin and eosin (H & E),
CD31 and collagen type IV to detect CNV area, amount and
density. Blood vessel formation was also confirmed with tomato
lectin immunostaining. The tissue sections were washed with 1 x
HEPES buffer for 15 min, blocked with 5% bovine serum albumin
for 30 min, and incubated with 1:50 dilution of goat polyclonal
antibody for collagen type IV (cat # sc-9302; Santa Cruz
Biotechnology Inc., Santa Cruz, CA) or CD31 (cat # sc-1506;
Santa Cruz) for 90 min followed by donkey anti-goat Alexa 594
secondary antibody (cat # A-11058; Invitrogen, Carlsbad, CA) at
1:500 dilution for 60 min. Lectin staining entailed the incubation
of corneal sections with 20 mg/ml Texas red-conjugated tomato
lectin (cat # TL-1176; Vector laboratories, Burlingame, CA) for
90 min. Tissue sections were washed in HEPES buffer and
mounted using Vectashield medium containing 49-6-diamidino-2-
phenylindole (DAPI; Vector laboratories). The stained sections
were viewed and photographed with a Leica fluorescent
microscope (Leica DM 4000B; Leica) equipped with a digital
camera (SpotCam RT KE).
Immunoblotting
The protein lysates were prepared by homogenizing corneas in
protein lysis buffer (5 mM EDTA, 150 mM NaCl, 0.002 M
phenylmethylsulfonyl fluoride, 50 mM Tris-HCl, pH 7.5) con-
taining 1 mL protease inhibitor cocktail (Roche Applied Sciences,
Indianapolis, IN). The sample was homogenized and incubated at
37uC for 30 minutes after adding 1 mL Nonidet P-40, 1 mL Tween
20, and 1 mL 20% sodium dodecyl sulphate, and centrifuged at
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16000 g for 15 minutes at 4uC. The same amount of protein of
each sample was suspended in Laemmli denaturing sample buffer,
vortexed and heated for 10 min at 70uC. The proteins were
resolved on 4–20% SDS-PAGE gel and transferred onto 0.45 mm
pore size PVDF membrane (Invitrogen, San Diego, CA). The
membrane was incubated with decorin (cat # sc-73896; Santa
Cruz) or CD31 (cat # sc-1506; Santa Cruz) or b-actin (cat # sc-
69879; Santa Cruz) or GAPDH (cat# sc-48166; Santa Cruz)
primary antibody followed by alkaline phosphatase-conjugated
anti-goat or anti-mouse secondary antibody (Santa Cruz). The
bands were visualized by NBT/BCIP. The gel data was analyzed
using National Institutes of Health Image J 1.38X (NIH, Bethesda,
MD) software.
RNA Extraction, cDNA Synthesis, and Real Time PCR
Corneal tissues were homogenized in RLT buffer using
TissueLyser (Qiagen Inc., Valencia, CA) for 2 min at 20 Hz.
Total RNA was extracted using RNeasy kit (Qiagen Inc.,
Valencia, CA), and reverse-transcribed to cDNA following
vendor’s instructions (Promega, Madison, WI). Briefly, tissues
were lysed in 350 ml RLT buffer (Qiagen Inc., Valencia, CA)
containing b-mercaptoethanol followed by 590 ml RNase free
water containing proteinase K solution. The solution was
incubated at 55uC for 10 min and centrifuged at 10,000 g for
5 min. Half the volume of ethanol was added to supernatant and
resulting solution was applied onto RNeasy column. The RNA
was eluted with 30 ml of RNAse free water and reverse transcribed
to cDNA using a commercial kit following vendor’s instructions by
carrying reverse transcription reaction at 42uC for 30 min
followed by enzyme inactivation with heat at 90uC for 2 min
(Promega). Semi-quantitative PCR reactions were performed to
determine VEGF, macrophage chemoattractant protein (MCP1),
pigmented epithelium-derived factor (PEDF), and angiopoietin
levels. A 20 ml reaction mixture containing 2 ml cDNA, 2 ml
forward (200 nM) and 2 ml reverse (200 nM) primer, 3.125 mM of
deoxynucleotide triphosphates (dNTPs) and Taq polymerase was
run one cycle at 95uC for 3 min, then 40 cycles of 95uC 30 s,
followed by 55uC 30 s and 55uC for 60 s, using a thermocycler
(Bio-Rad Laboratories, Hercules, CA). The VEGF forward and
reverse primer sequences were 59-ACC CAT GGC AGA AGA
AGG AGA CAA-39 and 59-ACT CCA GGC TTT CAT CAT
TGC AGC-39, the MCP1 forward and reverse primer sequences
were 59-TCG CTC AGC CAG ATG CAA TCA ATG-39 and 59-
TGG AAT CCT GAA CCC ACT TCT GCT-39, the PEDF
forward and reverse primer sequences were 59-TGA TGT CGG
ACC CTA AGG CTG TTT-39 and 59-ATG AAT GAA CTC
GGA GGT GAG GCT-39, the angiopoietin forward and reverse
primer sequences were 59-TTT GCT TTC CTC GCT GCC
ATT CTG-39 and 59-CAC ATT GCC CAT GTT GAA TCC
GGT-39 whereas the b-actin (a house keeping gene) gene’s
forward and reverse primer sequences were 59-CGG CTA CAG
CTT CAC CAC CA-39 and 59-CGG GCA GCT CGT AGC
TCT TC-39. Each PCR experiment was repeated at least three
times.
Transmission Electron Microscopy (TEM)
Rabbit corneas were fixed in TEM fixative and processed at the
University of Missouri Electron Microscopy Core. The 85 nm
ultrathin corneal sections were prepared using Leica Ultracut
UCT ultramicrotome and transferred onto a 200 mesh copper
grid for post-staining with uranyl acetate and Sato’s triple lead
stain. The samples were then imaged using JEOL 1400
transmission electron microscope (Tokyo, Japan).
Statistical Analysis
The CNV morphometry and quantitative PCR results are
expressed as mean6 standard error of the mean (SEM). Statistical
analysis of angiogenesis and PCR data was performed using two-
way analysis of variance (ANOVA) followed by Bonferroni
multiple comparisons test. A value of p,0.05 was considered
statistically significant.
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